IN2014CN04071A - - Google Patents
Download PDFInfo
- Publication number
- IN2014CN04071A IN2014CN04071A IN4071CHN2014A IN2014CN04071A IN 2014CN04071 A IN2014CN04071 A IN 2014CN04071A IN 4071CHN2014 A IN4071CHN2014 A IN 4071CHN2014A IN 2014CN04071 A IN2014CN04071 A IN 2014CN04071A
- Authority
- IN
- India
- Prior art keywords
- antigen
- tcdb
- relates
- tcda
- difficile
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB201121149A GB201121149D0 (en) | 2011-12-08 | 2011-12-08 | Clostridium difficile toxin-based vaccine |
GBGB1217321.7A GB201217321D0 (en) | 2012-09-27 | 2012-09-27 | Vaccine |
PCT/IB2012/002955 WO2013084071A2 (en) | 2011-12-08 | 2012-12-07 | Clostridium difficile toxin-based vaccine |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2014CN04071A true IN2014CN04071A (de) | 2015-10-23 |
Family
ID=47747684
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN4071CHN2014 IN2014CN04071A (de) | 2011-12-08 | 2012-12-07 |
Country Status (15)
Country | Link |
---|---|
US (1) | US9694063B2 (de) |
EP (1) | EP2788022B1 (de) |
JP (1) | JP6084631B2 (de) |
KR (1) | KR20140101835A (de) |
CN (1) | CN103974718A (de) |
AU (1) | AU2012349753A1 (de) |
BR (1) | BR112014013876A2 (de) |
CA (1) | CA2858519A1 (de) |
ES (1) | ES2704069T3 (de) |
IL (1) | IL232957A0 (de) |
IN (1) | IN2014CN04071A (de) |
MX (1) | MX2014006630A (de) |
RU (1) | RU2014127714A (de) |
SG (1) | SG11201402375VA (de) |
WO (1) | WO2013084071A2 (de) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG10201911993UA (en) | 2011-04-22 | 2020-02-27 | Wyeth Llc | Compositions relating to a mutant clostridium difficile toxin and methods thereof |
AU2013319821A1 (en) * | 2012-09-19 | 2015-02-26 | Novartis Ag | Clostridium difficile polypeptides as vaccine |
BR122016023101B1 (pt) | 2012-10-21 | 2022-03-22 | Pfizer Inc | Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile |
WO2014197651A1 (en) * | 2013-06-05 | 2014-12-11 | Tufts University | Atoxic recombinant holotoxins of clostridium difficile as immunogens |
CA3156357A1 (en) | 2014-01-06 | 2015-07-09 | The Trustees Of The University Of Pennsylvania | Pd1 and pdl1 antibodies and vaccine combinations and use of same for immunotherapy |
EP3160500B1 (de) * | 2014-06-25 | 2019-08-21 | GlaxoSmithKline Biologicals S.A. | Clostridium difficile immunogene zusammensetzung |
US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
US10668140B2 (en) | 2017-02-24 | 2020-06-02 | University Of South Floirida | Non-toxigenic Clostridium difficile spores for use in oral vaccination |
US10555992B2 (en) | 2017-05-31 | 2020-02-11 | University Of South Florida | Immunogenic proteins against clostridium difficile |
US10933126B2 (en) | 2018-05-03 | 2021-03-02 | The Board Of Regents Of The University Of Oklahoma | Clostridium difficile immunogenic compositions and methods of use |
EP3972638A4 (de) * | 2019-05-21 | 2023-09-13 | The Regents Of The University Of California | Impfstoffzusammensetzungen für clostridium difficile |
Family Cites Families (71)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US6090406A (en) | 1984-04-12 | 2000-07-18 | The Liposome Company, Inc. | Potentiation of immune responses with liposomal adjuvants |
US5916588A (en) | 1984-04-12 | 1999-06-29 | The Liposome Company, Inc. | Peptide-containing liposomes, immunogenic liposomes and methods of preparation and use |
US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
AU627226B2 (en) | 1988-08-25 | 1992-08-20 | Liposome Company, Inc., The | Influenza vaccine and novel adjuvants |
DE3841091A1 (de) | 1988-12-07 | 1990-06-13 | Behringwerke Ag | Synthetische antigene, verfahren zu ihrer herstellung und ihre verwendung |
ES2055785T3 (es) | 1989-01-17 | 1994-09-01 | Eniricerche Spa | Peptidos sinteticos y su uso como vehiculos universales para la preparacion de conjugados inmunogenos aptos para el desarrollo de vacunas sinteticas. |
HU212924B (en) | 1989-05-25 | 1996-12-30 | Chiron Corp | Adjuvant formulation comprising a submicron oil droplet emulsion |
WO1991001146A1 (en) | 1989-07-14 | 1991-02-07 | Praxis Biologics, Inc. | Cytokine and hormone carriers for conjugate vaccines |
IT1237764B (it) | 1989-11-10 | 1993-06-17 | Eniricerche Spa | Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici. |
GB2276169A (en) | 1990-07-05 | 1994-09-21 | Celltech Ltd | Antibodies specific for carcinoembryonic antigen |
ATE128628T1 (de) | 1990-08-13 | 1995-10-15 | American Cyanamid Co | Faser-hemagglutinin von bordetella pertussis als träger für konjugierten impfstoff. |
IT1262896B (it) | 1992-03-06 | 1996-07-22 | Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini. | |
DK0761231T3 (da) | 1992-06-25 | 2000-05-08 | Smithkline Beecham Biolog | Vaccinepræparat indeholdende adjuvanser |
IL102687A (en) | 1992-07-30 | 1997-06-10 | Yeda Res & Dev | Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them |
GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
US6239116B1 (en) | 1994-07-15 | 2001-05-29 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US6429199B1 (en) | 1994-07-15 | 2002-08-06 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules for activating dendritic cells |
EP1041149B8 (de) | 1994-10-24 | 2007-10-03 | Allergan, Inc. | Impfstoff und Antitoxine zur Behandlung und Vorbeugung von C. Difficile Krankheiten |
GB9513261D0 (en) | 1995-06-29 | 1995-09-06 | Smithkline Beecham Biolog | Vaccines |
CN1195297A (zh) | 1995-07-07 | 1998-10-07 | 奥拉瓦克斯有限公司 | 艰难梭菌毒素作为粘膜佐剂 |
US5707829A (en) | 1995-08-11 | 1998-01-13 | Genetics Institute, Inc. | DNA sequences and secreted proteins encoded thereby |
WO1998008540A1 (en) | 1996-08-28 | 1998-03-05 | Ophidian Pharmaceuticals, Inc. | Multivalent vaccine for clostridium botulinum neurotoxin |
JP5087758B2 (ja) | 1997-03-10 | 2012-12-05 | オタワ ホスピタル リサーチ インスティチュート | アジュバントとして非メチル化CpGジヌクレオチドを含む核酸の使用 |
GB9712347D0 (en) | 1997-06-14 | 1997-08-13 | Smithkline Beecham Biolog | Vaccine |
GB9713156D0 (en) | 1997-06-20 | 1997-08-27 | Microbiological Res Authority | Vaccines |
WO1998059053A1 (en) * | 1997-06-20 | 1998-12-30 | Queen Mary & Westfield College | Immonogenic fragments of toxin a of clostridium difficile |
ES2298316T3 (es) | 1997-09-05 | 2008-05-16 | Glaxosmithkline Biologicals S.A. | Emulsiones de aceite en agua que contienen saponinas. |
GB9725084D0 (en) | 1997-11-28 | 1998-01-28 | Medeva Europ Ltd | Vaccine compositions |
KR100585408B1 (ko) | 1998-02-12 | 2006-06-01 | 와이어쓰 홀딩스 코포레이션 | 인터루킨-12로 제형된 폐렴구균 및 수막구균 백신 |
US6303114B1 (en) | 1998-03-05 | 2001-10-16 | The Medical College Of Ohio | IL-12 enhancement of immune responses to T-independent antigens |
CN1296416A (zh) | 1998-04-09 | 2001-05-23 | 史密丝克莱恩比彻姆生物有限公司 | 佐剂组合物 |
US20020009429A1 (en) * | 1999-01-29 | 2002-01-24 | Galagen, Inc. | Pharmaceutical composition comprising a selected antigen and candida species antigen and methods |
EP1162999B1 (de) | 1999-03-19 | 2006-11-29 | Glaxosmithkline Biologicals S.A. | Impstoff gegen Streptococcus pneumoniae |
WO2000061761A2 (en) | 1999-04-09 | 2000-10-19 | Techlab, Inc. | Recombinant clostridium toxin a protein carrier for polysaccharide conjugate vaccines |
CA2365915C (en) | 1999-04-09 | 2015-11-24 | Techlab, Inc. | Recombinant toxin a/toxin b vaccine against clostridium difficile |
US6733760B1 (en) * | 1999-04-09 | 2004-05-11 | Techlab, Inc. | Recombinant toxin A/toxin B vaccine against Clostridium difficile |
GB0007432D0 (en) | 2000-03-27 | 2000-05-17 | Microbiological Res Authority | Proteins for use as carriers in conjugate vaccines |
WO2001085748A2 (en) * | 2000-05-10 | 2001-11-15 | Glycodesign Inc. | Designing modulators for glycosyltransferases |
EP2277894A1 (de) | 2000-10-27 | 2011-01-26 | Novartis Vaccines and Diagnostics S.r.l. | Nukleinsäure und Proteine von Gruppen A und B Streptokokken |
AU2002338233A1 (en) * | 2001-03-30 | 2002-10-15 | Basf Plant Science Gmbh | Glucan chain length domains |
US20030091593A1 (en) | 2001-09-14 | 2003-05-15 | Cytos Biotechnology Ag | In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles |
DK1450856T3 (da) | 2001-09-14 | 2010-05-31 | Cytos Biotechnology Ag | Pakning af immunstimulatorisk CpG i virus-lignende partilker, fremgangsmåde og anvendelse |
WO2004041857A2 (en) | 2002-06-17 | 2004-05-21 | Ballard Jimmy D | Mutant of clostridium difficile toxin b and methods of use |
US20040235139A1 (en) * | 2002-12-23 | 2004-11-25 | Demain Arnold L. | Clostridium difficile culture and toxin production methods |
EP2857418B1 (de) | 2004-02-06 | 2017-07-26 | University of Massachusetts | Antikörper gegen Clostridium difficile Toxine und ihre Verwendung |
CA2592015A1 (en) | 2004-12-27 | 2006-07-06 | Progenics Pharmaceuticals (Nevada), Inc. | Orally deliverable and anti-toxin antibodies and methods for making and using them |
US20060228369A1 (en) | 2005-04-11 | 2006-10-12 | Program For Appropriate Technology In Health | Stabilization and preservation of temperature-sensitive vaccines |
CN101500581B (zh) | 2006-06-08 | 2013-10-30 | 科内尔研究基金会 | 编码艰难梭菌毒素a和毒素b受体结合域的密码子优化dna分子及其使用方法 |
ES2507553T3 (es) | 2006-08-02 | 2014-10-15 | Johannes Gutenberg-Universität Mainz | Fármaco contra intoxicaciones por LCT |
EP2167119B1 (de) * | 2007-06-14 | 2016-08-24 | The Secretary of State for Health | Chemisch modifizierte peptide mit verbesserter immunogenität |
WO2008156676A1 (en) * | 2007-06-15 | 2008-12-24 | President And Fellows Of Harvard College | Methods and compositions for detecting and modulating o-glycosylation |
US20120020996A1 (en) * | 2008-08-06 | 2012-01-26 | Jonathan Lewis Telfer | Vaccines against clostridium difficile and methods of use |
AU2010215275B2 (en) | 2009-02-20 | 2016-03-31 | Micropharm Limited | Antibodies to Clostridium difficile toxins |
CA2772400A1 (en) * | 2009-08-27 | 2011-03-17 | Synaptic Research, Llc | A novel protein delivery system to generate induced pluripotent stem (ips) cells or tissue-specific cells |
US10046040B2 (en) | 2009-11-16 | 2018-08-14 | University Of Maryland, Baltimore | Multivalent live vector vaccine against Clostridium difficile-associated disease |
US20120282274A1 (en) | 2009-11-20 | 2012-11-08 | Northshore University Health System Research Institute | Targeting of the c-terminal segment of c.difficile toxin b for improved clinical diagnosis, prevention, and treatment |
JP2013512916A (ja) * | 2009-12-02 | 2013-04-18 | タフツ ユニバーシティー | 免疫原としてのClostridiumdifficileの無毒の組換えホロトキシン |
GB0921288D0 (en) | 2009-12-04 | 2010-01-20 | Health Prot Agency | Therapies for preventing or suppressing clostridium difficile infection |
JP5839411B2 (ja) | 2010-03-30 | 2016-01-06 | フェニックス インク. | 組み換え型毒素タンパク質の高レベルの発現 |
KR101820987B1 (ko) * | 2010-04-15 | 2018-01-22 | 프로제닉스 파머슈티컬스, 인코포레이티드 | 클로스트리듐 디피실리 관련 감염 및 질병의 치료를 위한 항체 |
WO2012028741A1 (en) | 2010-09-03 | 2012-03-08 | Intercell Ag | Isolated polypeptide of the toxin a and toxin b proteins of c. difficile and uses thereof |
US8431361B2 (en) | 2010-09-17 | 2013-04-30 | Board Of Regents Of The University Of Oklahoma | Bacterial cells, optimized nucleotide sequences and methods for improved expression of recombinant Clostridium difficile toxin B |
GB201016742D0 (en) | 2010-10-05 | 2010-11-17 | Health Prot Agency | Clostridium difficile antigens |
WO2012118693A1 (en) | 2011-02-28 | 2012-09-07 | Northshore University Healthsystem | Methods of diagnosing clostridium difficile infection |
SG10201911993UA (en) * | 2011-04-22 | 2020-02-27 | Wyeth Llc | Compositions relating to a mutant clostridium difficile toxin and methods thereof |
PL3564378T3 (pl) | 2011-05-27 | 2024-03-11 | Glaxosmithkline Biologicals Sa | Kompozycja immunogenna |
AR087716A1 (es) * | 2011-08-31 | 2014-04-09 | Valent Biosciences Corp | Composiciones reguladoras del crecimiento de plantas, metodos de preparacion y usos de las mismas |
AR089797A1 (es) * | 2012-01-27 | 2014-09-17 | Merck Sharp & Dohme | Vacunas contra clostridum difficile que comprenden toxinas recombinantes |
GB201223342D0 (en) * | 2012-12-23 | 2013-02-06 | Glaxosmithkline Biolog Sa | Immunogenic composition |
-
2012
- 2012-12-07 CA CA2858519A patent/CA2858519A1/en not_active Abandoned
- 2012-12-07 RU RU2014127714A patent/RU2014127714A/ru not_active Application Discontinuation
- 2012-12-07 JP JP2014545387A patent/JP6084631B2/ja active Active
- 2012-12-07 CN CN201280060487.1A patent/CN103974718A/zh active Pending
- 2012-12-07 IN IN4071CHN2014 patent/IN2014CN04071A/en unknown
- 2012-12-07 SG SG11201402375VA patent/SG11201402375VA/en unknown
- 2012-12-07 KR KR1020147018480A patent/KR20140101835A/ko not_active Application Discontinuation
- 2012-12-07 ES ES12826538T patent/ES2704069T3/es active Active
- 2012-12-07 WO PCT/IB2012/002955 patent/WO2013084071A2/en active Application Filing
- 2012-12-07 BR BR112014013876A patent/BR112014013876A2/pt not_active IP Right Cessation
- 2012-12-07 MX MX2014006630A patent/MX2014006630A/es unknown
- 2012-12-07 AU AU2012349753A patent/AU2012349753A1/en not_active Abandoned
- 2012-12-07 EP EP12826538.6A patent/EP2788022B1/de active Active
- 2012-12-07 US US14/363,387 patent/US9694063B2/en active Active
-
2014
- 2014-06-05 IL IL232957A patent/IL232957A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO2013084071A2 (en) | 2013-06-13 |
CA2858519A1 (en) | 2013-06-13 |
US9694063B2 (en) | 2017-07-04 |
CN103974718A (zh) | 2014-08-06 |
ES2704069T3 (es) | 2019-03-14 |
JP2015500827A (ja) | 2015-01-08 |
US20150132333A1 (en) | 2015-05-14 |
EP2788022A2 (de) | 2014-10-15 |
WO2013084071A3 (en) | 2013-11-07 |
AU2012349753A1 (en) | 2014-06-19 |
EP2788022B1 (de) | 2018-10-31 |
RU2014127714A (ru) | 2016-01-27 |
BR112014013876A2 (pt) | 2019-09-24 |
JP6084631B2 (ja) | 2017-02-22 |
KR20140101835A (ko) | 2014-08-20 |
SG11201402375VA (en) | 2014-10-30 |
MX2014006630A (es) | 2014-07-09 |
IL232957A0 (en) | 2014-07-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IN2014CN04071A (de) | ||
MX2013011479A (es) | Anticuerpos anti-fgfr4 y metodos de uso. | |
IL242934B (en) | Microbiota restoration therapy (mrt) compounds and methods of manufacture | |
TN2015000050A1 (en) | Methods of treating a tauopathy | |
NZ715815A (en) | High-stability t-cell receptor and preparation method and application thereof | |
PH12014501427B1 (en) | Anti-phf-tau antibodies and their uses | |
MX2014004022A (es) | Anticuerpos anti-htra1 y metodos de uso. | |
MX2013015311A (es) | Polipeptidos de enlace de pcsk9 y metodos de uso. | |
CR20150046A (es) | Anticuerpos anti-cd79b e inmunoconjugados | |
MX2014002053A (es) | Anticuerpos anti -mcsp y metodos de uso. | |
MX2013007168A (es) | Anticuerpo anti-pcsk9 y metodos de uso. | |
IN2014DN05885A (de) | ||
TN2013000378A1 (en) | Anti - sclerostin antibody crystals and formulations thereof | |
MX340555B (es) | Anticuerpos contra il-18r1 y usos de los mismos. | |
AU337887S (en) | Allsaw | |
AU2013225816A8 (en) | Compositions and methods for treating Type III Gaucher Disease | |
EP4023243A3 (de) | Zusammensetzungen und verfahren zur behandlung von zöliakie/sprue | |
MX357675B (es) | Anticuerpos anti-jagged y métodos de uso. | |
WO2013123046A3 (en) | Cathode buffer materials and related devices and methods | |
PH12015501854A1 (en) | Factor ix polypeptide formulations | |
UA112760C2 (uk) | Теобромін у комбінації з гвайфенезином для лікування кашлю | |
MX2023003000A (es) | Formulaciones de liberacion modificada de viloxacina. | |
IN2015DN00820A (de) | ||
AU337888S (en) | Allsaw | |
GB201114923D0 (en) | Immunogenic proteins and compositions |